03:41 AM EDT, 03/28/2024 (MT Newswires) -- Stoke Therapeutics ( STOK ) said late Wednesday it priced an upsized $125 million public stock offering at $13.50 per share.

The company is offering about 5.6 million of its common shares and pre-funded warrants to purchase up to 3.7 million shares. The underwriters have been granted a 30-day option to buy up to an additional 1.4 million shares.

The offering is expected to close on or about April 2.

Stoke aims to use the proceeds from the offering, combined with its existing cash and cash equivalents, to fund research, clinical testing and development of its product candidates, as well as for general corporate purposes.